Sponsor:
Corteria Pharmaceuticals
Code:
NCT06815471
Conditions
Worsening Heart Failure
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
COR-1167
Placebo
Brief summary:
Conditions
Worsening Heart Failure
Study ID
NCT06815471
Start date
Aug 7, 2025
Status verified date
Nov, 2026
Completion date
Jul, 2027
Anticipated
Primary completion date
Jul, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Enrollment
210 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: COR-1167 low dose
placebo comparator: Placebo
Interventions
COR-1167
Placebo
Primary outcome measure
Central contacts
Clinical Operations Director
Brian.Sontag@Corteriapharma.comLocations
NC Heart and Vascular Research, LLC
Recruiting
Raleigh, North Carolina, United States, 27607
Ohio State University
Recruiting
Columbus, Ohio, United States, 43210
Sponsor
Corteria Pharmaceuticals
Last update posted
Nov 16, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by Corteria Pharmaceuticals on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.